Home
DR. VADIM JUCAUD'S LABORATORY
ABOUT DR. VADIM JUCAUD
Dr. Vadim Jucaud is an Assistant Professor at the Terasaki Institute for Biomedical Innovation (TIBI). Dr. Jucaud has been part of the Terasaki Laboratory since 2010, where he started his research career under the mentorship of Professor Paul I. Terasaki in the fields of histocompatibility and immunogenetics, with a particular emphasis on HLA antibodies and the Humoral Theory of Transplantation. Dr. Jucaud has a Ph.D. in Immunology and Microbiology, specializing in transplant immunology and Human Leukocyte Antigen (HLA) immunobiology, notably in the diversity, detection, and prediction of the humoral response against HLA molecules. Dr. Jucaud is an expert in HLA immunogenetics, histocompatibility, and immunogenicity. In addition, he has excellent technical skills forged by 12 years of experience in characterizing the humoral immune response in transplant patients, T and B cell immunomodulation, sensitive multiplex immunoassays, antibody cross-reactivity and immunogenic antibody epitopes, and HLA antibody/antigen interactions. Dr. Jucaud received the American Transplant Congress Young Investigator Award in 2018 for his outstanding work demonstrating the prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients. With the establishment of TIBI in 2020, Dr. Jucaud has been leading the organs-on-a-chip and biosensors team. Motivated by his background and the exciting multidisciplinary research at TIBI, Dr. Jucaud is proposing a unique approach to combine HLA immunobiology, organ-on-a-chip technologies, tissue engineering, biomaterials, and biosensors for developing novel immunocompetent organs-on-a-chip platforms and microphysiological systems. The long-term objective of Dr. Jucaud's lab is to engineer innovative in vitro models recapitulating complex biological mechanisms of organ physiology and disease states to be considered by regulatory authorities as an indispensable step in accelerating drug discovery and development pipelines and promoting personalized medicine applications while reducing the need for animal model testing. Dr. Jucaud has authored over 54 peer-reviewed publications and 32 conference abstracts, with an h-index of 19 and over 1,060 citations.
RESEARCH OVERVIEW
Dr. Vadim Jucaud’s Lab is recognized for its vibrant and collaborative research environment, where multidisciplinary teams thrive and innovation flourishes. With access to state-of-the-art facilities and cutting-edge equipment, scientists in the lab are empowered to push the boundaries of scientific discovery in four major research thematic areas: (1) Organ on-a-chip models; (2) Organ transplantation; (3) Biosensors and biomarker detection; and (4) biomaterials. These research thematics seamlessly overlap, thus fostering a holistic approach to advancing biomedical innovation. The first thematic on organs on-a-chip revolutionizes our understanding of organ physiology and disease modeling, offering novel platforms for drug testing and personalized medicine. Complementing this, Jucaud’s lab expertise in organ transplantation develops novel approaches to improving transplant outcomes through innovative bioengineering techniques and biomaterials, addressing critical challenges in tissue compatibility and allograft rejection. Furthermore, Jucaud’s lab research in biosensors and biomarker detection develops new diagnostic tools with enhanced sensitivity and specificity, promising early detection and real-time monitoring of various diseases using various bodily fluid samples. Lastly, exploring biomaterials underscores the importance of designing materials that mimic the complexity of biological systems, facilitating tissue regeneration and medical device development. By intertwining these thematic areas, Dr. Jucaud’s Lab not only advances fundamental scientific understanding but also underscores the clinical relevance of its research. The development of organs on-a-chip technologies and biomaterials holds immense potential for revolutionizing clinical practice, enabling more accurate disease modeling, drug screening, and personalized treatment approaches. Similarly, breakthroughs in organ transplantation and biosensors offer hope for improving patient outcomes, reducing transplant rejection rates, and enabling early disease detection, thereby translating laboratory discoveries into tangible benefits for healthcare. Dr. Jucaud Lab's collaborative environment and dedication to high-quality research ensure that its endeavors continue to make significant strides toward addressing pressing medical challenges and improving patient care on a global scale.
Organs-on-a-chip platforms and applications
Dr. Jucaud's Lab is pioneering efforts to democratize Organ-on-a-Chip (OoC) technologies, making them more accessible and applicable in clinical settings worldwide. By significantly reducing fabrication costs and the reliance on expensive facilities and equipment, they are making strides toward translating these innovations into practical clinical applications. For instance, developing a lymph node on-a-chip model could revolutionize cancer treatment by enabling researchers to simulate the complex interactions between cancer cells and the immune system. This could lead to developing more effective cancer vaccines tailored to individual patients, ultimately improving treatment outcomes. In organ transplantation, Dr. Jucaud's Lab's liver on-a-chip model holds promise for enhancing organ preservation techniques and reducing the risk of organ rejection. By mimicking the physiological environment of the liver, this technology could improve the viability of donor organs and increase the success rates of transplant procedures. Their work on the blood-brain barrier on-a-chip allows researchers to study the permeability of drugs across the blood-brain barrier in a controlled environment. This could facilitate the development of more targeted drug delivery systems for treating neurological disorders such as Alzheimer's disease and Parkinson's disease. Moreover, their glioblastoma on-a-chip model offers new avenues for studying the progression of brain cancer and testing potential therapeutic interventions. By recreating the tumor microenvironment, researchers can screen drugs more efficiently and identify novel treatment strategies to combat this deadly disease. Overall, the advancements made by Dr. Jucaud's Lab in OoC technologies have the potential to revolutionize various aspects of clinical practice, from personalized medicine and drug delivery to organ transplantation and cancer treatment. As these technologies continue to evolve and become more accessible, they hold great promise for improving patient outcomes and advancing biomedical innovation.
Organs on-a-chip models
Lymph node on-a-chip
Microvascular bed on-a-chip
Liver on-a-chip
Blood-brain barrier on-a-chip
Glioblastoma on-a-chip
Wound on-a-chip
Applications and translation
Cancer vaccines
Organ transplantation
Opioid metabolism
Drug screening and off-target toxicity assessment
Personalized medicine
Drug delivery
Chronic wound treatment
Transplant immunology and HLA immunobiology
Dr. Jucaud's lab focuses on unraveling the complexities surrounding donor-specific HLA antibodies in organ transplant recipients. Their research encompasses three primary objectives: (1) describing the prevalence, incidence rates, and clinical impact of HLA antibodies; (2) characterizing HLA antibody epitopes; and (3) predicting HLA immunogenicity. Through meticulous analysis, they aim to shed light on the clinical significance of HLA antibodies, identify specific epitopes involved in antibody-antigen interactions, and develop predictive models for immune responses to HLA mismatches. Additionally, their work extends into transplant tolerance, exploring mechanisms by which the immune system can accept donor organs without long-term immunosuppression. Dr. Jucaud's lab strives to improve patient care and transplant outcomes through personalized approaches and novel therapeutic strategies by advancing our understanding of immune responses in organ transplantation.
Biosensors and biomarker detection
Biosensors play a crucial role in characterizing biological systems, offering diverse modalities for detecting and quantifying biomarkers with high sensitivity and specificity. Dr. Jucaud's lab explores various biosensing modalities, including label-free electrochemical sensors, label-free optical sensors, TEER (trans-epithelial electrical resistance) sensors, solid-phase immunoassays such as Luminex and ELISA, and micro cell-based ELISA. For instance, label-free electrochemical sensors utilize changes in electrical properties to detect biomolecular interactions, offering real-time monitoring capabilities. This technology has been integrated with organ-on-a-chip platforms to assess drug-induced changes in cellular behavior or evaluate the efficacy of therapeutic interventions. In another example, solid-phase immunoassays like Luminex and ELISA enable the sensitive detection and quantification of specific biomarkers, facilitating applications such as monoclonal antibody screening and characterization. Moreover, biosensors have found novel applications in exosome detection and quantification, enabling the isolation and analysis of extracellular vesicles for diagnostic and therapeutic purposes. Furthermore, biosensors have been adapted for real-time monitoring of cell secretome, allowing researchers to track the dynamic secretion of proteins and signaling molecules from cells cultured within organ-on-a-chip devices. This capability enables the study of cellular responses to environmental cues or drug treatments in a physiologically relevant context, facilitating the identification of biomarkers indicative of cellular health or disease states. The development of contact lens biosensors also represents an innovative approach for non-invasive monitoring of biomarkers in ocular fluids, offering potential applications in disease diagnosis and management. Biosensors play an important role in biomarker detection and offer versatile applications across various research areas and clinical settings. Integrating biosensing technologies with organ-on-a-chip platforms enhances their utility for studying complex biological systems and facilitates translation into clinical practice by providing valuable insights into disease mechanisms, drug efficacy, and patient-specific responses to therapy.
Biosensing modalities
Label-free electrochemical sensors
Label-free Optical sensors
TEER sensors
Solid-phase immunoassays (Luminex and ELISA)
Micro cell-based ELISA
Applications and translation
Monoclonal antibody screening and characterization
Exosome detection and quantification
Real-time monitoring of cell secretome
Contact lens biosensors
Biomaterials
In Dr. Jucaud's lab, research in biomaterials is characterized by a comprehensive exploration of various classes of biomaterials, each with specific attributes and potential clinical applications. In conjunction with organ-on-a-chip technologies and biosensors, Dr. Jucaud's lab explores synergistic opportunities to enhance the functionality and clinical translation of biomaterials. By integrating biomaterials with organ-on-a-chip platforms, researchers can create sophisticated microphysiological systems that closely mimic the complexity of human organs, enabling more accurate evaluation of biomaterial performance in physiologically relevant environments. For example, GelMA-based biomaterials can be incorporated into organ-on-a-chip devices to provide structural support for engineered tissues and facilitate the study of drug delivery mechanisms or wound healing processes in a controlled microenvironment. Additionally, integrating oxygen-releasing microparticles into organ-on-a-chip systems can simulate oxygen gradients present in vivo, enabling researchers to investigate tissue oxygenation dynamics and assess the efficacy of oxygen-releasing biomaterials in enhancing organ function and viability. The development of oxygen-releasing microparticles addresses the critical need for oxygenation in ischemic tissues, offering potential solutions for wound healing and organ preservation. Moreover, biosensors embedded within biomaterial matrices offer real-time monitoring capabilities, allowing researchers to track cellular responses, drug release kinetics, or biomarker concentrations within organ-on-a-chip models. Integrating biomaterials, organ-on-a-chip technologies, and biosensors enables synergistic advancements in drug screening, disease modeling, and personalized medicine, ultimately accelerating the translation of research findings into clinical applications and improving patient care. These biomaterials are bound to revolutionize clinical practice across various fields, including drug delivery systems tailored for specific therapeutic agents, wound dressings promoting accelerated healing, organ preservation solutions enhancing transplant success rates, tissue-engineered constructs for regenerative medicine, and advanced sealants for surgical interventions. Dr. Jucaud's lab aims to bridge the gap between biomaterial innovations and clinical implementation through meticulous research and translation efforts, ultimately improving patient care and outcomes in diverse medical settings.
Class of biomaterials
GelMA-based biomaterials
Oxygen-releasing microparticle
Ionogel adhesive
Natural rubber latex
Applications and translation
Drug delivery
Wound healing
Organ preservation
Tissue engineering
Sealants
TEAM MEMBERS
Dr. Jucaud's lab comprises a highly interdisciplinary research team specialized in HLA immunobiology, organ-on-a-chip technologies, tissue engineering, biomaterials, and biosensors, creating a creative environment with complementary knowledge.
Postdoctoral Researchers
Abdul Rahim Chethikkattuveli Salih
(OoC technologies, in vitro vascularization, and disease modeling)
Danial Khorsandi
(Microfabrication, microfluidic-based biosensors, and liver on-a-chip models)
Rafaela Ferrao – Fullbright Scholar
(nanoparticle drug delivery, and brain senescence)
Alumni
.jpg)
Jia-Wei Yang
Surjendu Maity
.jpg)
Arne Peirsman
 Li (1).jpg)
Shaopei Li
.jpg)
Huu Tuan Nguyen
Satoru Kawakita
Ana Lopez Hernandez
.jpg)
Can Yilgor
 Donizetti Herculano (1).jpg)
Rondinelli Herculano
.jpg)
Lei Mou
Praveen Bandaru
.jpg)
Christian Umemura
.jpg)
Gang Ge
.jpg)
Kalpana Mandal
Christpher Jewell
RESEARCH PAPERS
1. Rezaei Z, Navarro Torres A, Ge D, Wang T, Méndez Terán EC, García Vera SE, Bassous NJ, Soria OYP, Ávila Ramírez AE, Flores Campos LM, Azuela Rosas DA, Hassan S, Khorsandi D, Jucaud V, Hussain MA, Khateeb A, Zhang YS, Lee H, Kim DH, Khademhosseini A, Dokmeci MR, Shin SR. Noninvasive and Continuous Monitoring of On-Chip Stem Cell Osteogenesis Using a Reusable Electrochemical Immunobiosensor. ACS Sens. 2024; Apr 19. doi: 10.1021/acssensors.3c02165.
2. Jiang C, Chao CC, Li J, Ge X, Jucaud V, Cheng C, Shen X. A Role of Tissue-Resident Memory T Cells on Melanoma Prognosis: Insights from Singlecell RNA Sequencing Data. iScience. 2024;27(3):109277. doi: 10.1016/j.isci.2024.109277.
3. Herculano RD, Dos Reis CE, de Souza SMB, Pegorin Brasil GS, Scontri M, Kawakita S, Carvalho BG, Bebber CC, Su Y, de Sousa Abreu AP, Mecwan MM, Mandal K, Fusco Almeida AM, Mendes Giannini MJS, Guerra NB, Mussagy CU, Bosculo MRM, Gemeinder JLP, de Almeida BFM, Floriano JF, Farhadi N, Monirizad M, Khorsandi D, Nguyen HT, Gomez A, Tirpáková Z, Peirsman A, da Silva Sasaki JC, He S, Forster S, Burd BS, Dokmeci MR, Terra-Garcia M, Junqueira JC, de Mendonça RJ, Cardoso MR, Dos Santos LS, Silva GR, Barros NR, Jucaud V, Li B. Amphotericin B-loaded natural latex dressing for treating Candida albicans wound infections using Galleria mellonella model. J Control Release. 2023; 13;365:744-758. doi: 10.1016/j.jconrel.2023.12.010.
4. Kawakita S, Li S, Nguyen HT, Maity S, Haghniaz R, Bahari J, Yu N, Mandal K, Bandaru P, Mou L, Ermis M, Khalil E, Khosravi S, Peirsman A, Nasiri R, Adachi A, Nakayama A, Bell R, Zhu Y, Jucaud V, Dokmeci MR, Khademhosseini A. Rapid integration of screen-printed electrodes into thermoplastic organ-on-a-chip devices for real-time monitoring of trans-endothelial electrical resistance. Biomedical Microdevices. 2023; 25:37. doi: 10.1007/s10544-023-00669-9.
5. Abdalla G, Mussagy CU, Sant'Ana Pegorin Brasil G, Scontri M, da Silva Sasaki JC, Su Y, Bebber C, Rocha RR, de Sousa Abreu AP, Goncalves RP, Burd BS, Pacheco MF, Romeira KM, Picheli FP, Guerra NB, Farhadi N, Floriano JF, Forster S, He S, Nguyen HT, Peirsman A, Tirpáková Z, Huang S, Dokmeci MR, Ferreira ES, dos Santos LS, Piazza RD, Marques RFC, Goméz A, Jucaud V, Li B, de Azeredo HMC, Herculano RD. Eco-sustainable coatings based on chitosan, pectin, and lemon essential oil nanoemulsion and their effect on strawberry preservation. International Journal of Biological Macromolecules. 2023;126016. doi: 10.1016/j.ijbiomac.2023.126016.
6. Herculano RD, Dos Santos TO, de Barros NR, Pegorin Brasil GS, Scontri M, Carvalho BG, Mecwan M, Farhadi N, Kawakita S, Perego CH, Carvalho FA, Dos Santos AG, Guerra NB, Floriano JF, Mussagy CU, Tirpáková Z, Khorsandi D, Peirsman A, Nguyen HT, Gomez A, Mandal K, de Mendonça RJ, Li B, Dokmeci MR, Jucaud V. Aloe vera-loaded natural rubber latex dressing as a potential complementary treatment for psoriasis. Int J Biol Macromol. 2023; 11;242(Pt 1):124779. doi: 10.1016/j.ijbiomac.2023.124779.
7. de Souza Silva FK, Orlandi CBC, Fernandes MA, Sant'Ana Pegorin Brasil G, Mussagy CU, Scontri M, Sasaki JC, de Sousa Abreu AP, Guerra NB, Floriano JF, de Mendonça RJ, Caetano GF, Farhadi N, Gómez A, Huang S, Farias AM, Primo FL, Li B, Almeida AMF, Dokmeci MR, Jucaud V, Giannini MJSM, Cardoso MR, Herculano RD. Biocompatible anti-aging face mask prepared with curcumin and natural rubber with antioxidant properties. Int J Biol Macromol. 2023; 10:124778. doi: 10.1016/j.ijbiomac.2023.124778.
8. Wilson N, Reese S, Ptak L, Aziz F, Parajuli S, Jucaud V, Denham S, Mishra A, Cascalho M, Platt JL, Hematti P, Djamali A. Ixazomib for Desensitization (IXADES) in Highly Sensitized Kidney Transplant Candidates: A Phase II Clinical Trial. Kidney360. 2023 Mar 23. doi: 10.34067/KID.0000000000000113. Epub ahead of print. PMID: 36951387.
9. Mandal K, Sangabathuni S, Haghniaz R, Mecwan M, Kawakita S, Nakayama A, Zhang C, Edalati E, Huang W, Hernandez AL, Jucaud V, Dokmeci MR, Khademhosseini A. Oxygen-generating microparticles downregulate HIF-1α expression, increase cardiac contractility, and mitigate ischemic injury. Acta Biomaterialia. 2023; 159: 211-225. doi: 10.1016/j.actbio.2023.01.030.
10. Ge G, Mandal K, Haghniaz R, Li M, Xiao X, Carlson L, Jucaud V, Dokmeci MR, Ho GW, Khademhosseini A. Deep Eutectic Solvents-Based Ionogels with Ultrafast Gelation and High Adhesion in Harsh Environments. Adv. Funct. Mater. 2023, 2207388. doi: 10.1002/adfm.202207388.
11. Mecwan MM, Haghniaz R, Hassani A, Mandal K, Jucaud V, John JV, and Khademhosseini A. Thermoresponsive shear-thinning hydrogel (T-STH) hemostats for minimally invasive treatment of external hemorrhages. Biomater Sci. 2023. Accepted 12/7/22. doi: 10.1039/D2BM01559E.
12. Zhu Y, Nasiri R, Davoodi E, Zhang S, Saha S, Linn M, Jiang L, Haghniaz R, Hartel MC, Jucaud V, Dokmeci MR, Herland A, Toyserkani E, Khademhosseini A. A Microfluidic Contact Lens to Address Contact Lens-Induced Dry Eye. Small. 2022:2207017. doi:10.1002/smll.202207017.
13. de Paiva MB, Pegorin Brasil GS, Destro Chagas AL, Macedo AP, Ramos J, Mardegan Issa JP, Gangrade A, Ferreira Floriano J, Ferreira Caetano G, Li B, Farhadi N, Mandal K, Dokmeci MR, Jucaud V, Herculano RD, and Shimano AC. Latex-collagen membrane: an alternative treatment for tibial bone defects. J Mater Sci. 2022. doi: 10.1007/s10853-022-08009-7.
14. Li S, Zhu Y, Haghniaz R, Kawakita S, Guan S, Chen J, Li Z, Mandal K, Bahari J, Shah S, Guo J, Kang H, Sun W, Kim H-J, Jucaud V, Dokmeci MR, Kollbaum P, Lee CH, Khademhosseini A. A Microchambers Containing Contact Lens for the Noninvasive Detection of Tear Exosomes. Adv Funct Mater. 2022:2206620. doi: 10.1002/adfm.202206620.
15. Zhu Y, Hartel MC, Yu N, Garrido PR, Kim S, Lee J, Bandaru P, Guan S, Lin H, Emaminejad S, de Barros NR, Ahadian S, Kim H-J, Sun W, Jucaud V, Dokmeci MR, Weiss PS, Yan R, Khademhosseini A. Epidermis-Inspired Wearable Piezoresistive Pressure Sensors Using Reduced Graphene Oxide Self-Wrapped Copper Nanowire Networks. Small Methods. 2022;6(1):2100900. doi: 10.1002/smtd.202100900.
16. Lee J, Wang Y, Xue C, Chen Y, Qu M, Thakor J, Zhou X, Barros NR, Falcone N, Young P, van den Dolder FW, Lee K, Zhu Y, Cho H-J, Sun W, Zhao B, Ahadian S, Jucaud V, Dokmeci MR, Khademhosseini A, Kim H-J. pH-Responsive doxorubicin delivery using shear-thinning biomaterials for localized melanoma treatment. Nanoscale. 2022;14(2):350-60. doi: 10.1039/D1NR05738C.
17. Zhu Y, Kim S, Ma X, Byrley P, Yu N, Liu Q, Sun X, Xu D, Peng S, Hartel MC, Zhang S, Jucaud V, Dokmeci MR, Khademhosseini A, Yan R. Ultrathin-shell epitaxial Ag@Au core-shell nanowires for high-performance and chemically-stable electronic, optical, and mechanical devices. Nano Research. 2021;14(11):4294-303. doi: 10.1007/s12274-021-3718-z.
18. Kawakita S, Beaumont JL, Jucaud V, Everly MJ. Personalized prediction of delayed graft function for recipients of deceased donor kidney transplants with machine learning. Scientific Reports. 2020;10(1):18409. doi: 10.1038/s41598-020-75473-z.
19. Jucaud V, Nguyen A, Tran B, Hopfield J, Pham T. Validation and cross-reactivity pattern assessment of monoclonal antibodies used for the screening of donor-specific IgG antibody subclasses in transplant recipients. Journal of Immunological Methods. 2020; 486: 112847. doi: 10.1016/j.jim.2020.112847.
20. Chen Y, Zhang S, Cui Q, Ni J, Wang X, Cheng X, Alem H, Tebon P, Xu C, Guo C, Nasiri R, Moreddu R, Yetisen AK, Ahadian S, Ashammakhi N, Emaminejad S, Jucaud V, Dokmeci MR, Khademhosseini A. Microengineered poly(HEMA) hydrogels for wearable contact lens biosensing. Lab on a Chip. 2020;20(22):4205-14. doi: 10.1039/D0LC00446D.
21. Jucaud V, Shaked A, DesMarais M, Sayre P, Feng S, Levitsky J, Everly MJ. Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients. Hepatology. 2019;69(3):1273-86. doi: 10.1002/hep.30281.
22. Ravindranath MH, Jucaud V, Ferrone S. Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers. J Immunol Methods. 2017;450:73-80. Epub 2017/08/08. doi: 10.1016/j.jim.2017.07.016. PubMed PMID: 28782523.
23. Ravindranath MH, Jucaud V, Banuelos N, Everly MJ, Cai J, Nguyen A, Terasaki PI. Nature and Clonality of the Fluoresceinated Secondary Antibody in Luminex Multiplex Bead Assays Are Critical Factors for Reliable Monitoring of Serum HLA Antibody Levels in Patients for Donor Organ Selection, Desensitization Therapy, and Assessment of the Risk for Graft Loss. J Immunol. 2017;198(11):4524-38. Epub 2017/05/10. doi: 10.4049/jimmunol.1700050. PubMed PMID: 28476933.
24. Jucaud V, Ravindranath MH, Terasaki PI. Conformational Variants of the Individual HLA-I Antigens on Luminex Single Antigen Beads Used in Monitoring HLA Antibodies: Problems and Solutions. Transplantation. 2017;101(4):764-77. doi: 10.1097/TP.0000000000001420.
25. Jucaud V. The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA. J Immunol Res. 2017;2017:2748614. doi: 10.1155/2017/2748614. PubMed PMID: 28331856; PMCID: PMC5346368 of this paper.
26. Hilali FE, Jucaud V, Hilali HE, Bhuiyan MH, Mancuso A, LiuSullivan N, Elidrissi A, Mazouz H. Characterization of the Anti-HLA Class I and II IgG Antibodies in Moroccan IVIg Using Regular Beads and Ibeads in Luminex Multiplex Single Antigen Immunoassay. International Journal of Immunology. 2017;5(4):53-65.
27. Ravindranath MH, Jucaud V, Maehara CY, Terasaki PI. Significance of the differences in the prevalence of anti-HLA antibodies in matched pairs of mother’s and cord blood. Immunology Letters. 2016;170:68-79. doi: https://doi.org/10.1016/j.imlet.2015.11.016.
28. Jucaud V, Ravindranath MH, Terasaki PI, Morales-Buenrostro LE, Hiepe F, Rose T, Biesen R. Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies. Clinical and Experimental Immunology. 2016;183(3):326-40. doi: 10.1111/cei.12724.
29. Ravindranath MH, Terasaki PI, Pham T, Jucaud V. The Monospecificity of Novel Anti-HLA-E Monoclonal Antibodies Enables Reliable Immunodiagnosis, Immunomodulation of HLA-E, and Upregulation of CD8+ T Lymphocytes. Monoclon Antib Immunodiagn Immunother. 2015;34(3):135-53. Epub 2015/06/20. doi: 10.1089/mab.2014.0096. PubMed PMID: 26090591.
30. Ravindranath MH, Terasaki PI, Maehara CY, Jucaud V, Kawakita S, Pham T, Yamashita W. Immunoglobulin (Ig)G purified from human sera mirrors intravenous Ig human leucocyte antigen (HLA) reactivity and recognizes one's own HLA types, but may be masked by Fab complementarity-determining region peptide in the native sera. Clin Exp Immunol. 2015;179(2):309-28. Epub 2014/09/10. doi: 10.1111/cei.12450. PubMed PMID: 25196542; PMCID: PMC4298408.
31. Zhu D, Ravindranath MH, Terasaki PI, Miyazaki T, Pham T, Jucaud V. Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg. Clin Exp Immunol. 2014;177(2):464-77. Epub 2014/03/13. doi: 10.1111/cei.12307. PubMed PMID: 24611451; PMCID: PMC4226597.
32. Sasaki T, Ravindranath MH, Terasaki PI, Freitas MC, Kawakita S, Jucaud V. Gastric cancer progression may involve a shift in HLA-E profile from an intact heterodimer to β2-microglobulin-free monomer. International Journal of Cancer. 2014;134(7):1558-70. doi: 10.1002/ijc.28484.
33. Ravindranath MH, Terasaki PI, Pham T, Jucaud V, Kawakita S. Suppression of blastogenesis and proliferation of activated CD4(+) T cells: intravenous immunoglobulin (IVIg) versus novel anti-human leucocyte antigen (HLA)-E monoclonal antibodies mimicking HLA-I reactivity of IVIg. Clin Exp Immunol. 2014;178(1):154-77. Epub 2014/06/04. doi: 10.1111/cei.12391. PubMed PMID: 24889882; PMCID: PMC4360205.
34. Ravindranath MH, Terasaki PI, Pham T, Jucaud V, Kawakita S. Therapeutic preparations of IVIg contain naturally occurring anti–HLA-E antibodies that react with HLA-Ia (HLA-A/-B/-Cw) alleles. Blood. 2013;121(11):2013-28. doi: 10.1182/blood-2012-08-447771.
REVIEW PAPERS
1. Marques PAC, Guerra NB, Dos Santos LS, Mussagy CU, Sant'Ana Pegorin Brasil G, Burd BS, Su Y, da Silva Sasaki JC, Scontri M, de Lima Lopes Filho PE, Silva GR, Miranda MCR, Ferreira ES, Primo FL, Fernandes MA, Crotti AEM, He S, Forster S, Ma C, de Barros NR, de Mendonça RJ, Jucaud V, Li B, Herculano RD, Floriano JF. Natural rubber latex-based biomaterials for drug delivery and regenerative medicine: Trends and directions. Int J Biol Macromol. 2024;16:131666. doi: 10.1016/j.ijbiomac.2024.131666.
2. Khorsandi D, Yang JW, Foster S, Khosravi S, Hosseinzadeh Kouchehbaghi N, Zarei F, Lee YB, Runa F, Gangrade A, Voskanian L, Adnan D, Zhu Y, Wang Z, Jucaud V, Dokmeci MR, Shen X, Bishehsari F, Kelber JA, Khademhosseini A, de Barros NR. Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients. Adv. Healthcare Mater. 2024; 2302331. https://doi.org/10.1002/adhm.202302331.
3. Zare EN, Khorsandi D, Zarepour A, Yilmaz H, Agarwal T, Hooshmand S, Mohammadinejad R, Ozdemir F, Sahin O, Adiguzel S, Khan H, Zarrabi A, Sharifi E, Kumar A, Mostafavi E, Hosseinzadeh Kouchehbaghi N, Mattoli V, Zhang F, Jucaud V, Hassani Najafabadi A, Khademhosseini A. Biomedical applications of engineered heparin-based materials. Bioactive Materials. 2024; 31:87-118. doi: 10.1016/j.bioactmat.2023.08.002.
4. Mohaghegh N, Ahari A, Zehtabi F, Buttles C, Davani S, Hoang H, Tseng K, Zamanian B, Khosravi S, Daniali A, Kouchehbaghi NH, Thomas I, Nouri H, D Khorsandi, Abasgholizadeh R, Akbari M, Patil R, Kang H, Jucaud V, Khademhosseini A, and Hassani Najafabadi A. Injectable Hydrogels for Personalized Cancer Immunotherapies. Acta Biomaterialia. 2023;172:67-91. doi: 10.1016/j.actbio.2023.10.002.
5. Falcone N, Ermis M, Tamay DG, Mecwan M, Monirizad M, Mathes TG, Jucaud V, Choroomi A, Barros N, Zhu Y, Vrana NE, Kraatz HB, Kim HJ, Khademhosseini A. Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery. Adv. Healthcare Mater. 2023; 2301096. doi: 10.1002/adhm.202301096.
6. Karamikamkar S, Yalcintas EP, Haghniaz R, de Barros NR, Mecwan M, Nasiri R, Davoodi E, Nasrollahi F, Erdem A, Kang H, Lee J, Zhu Y, Ahadian S, Jucaud V, Maleki H, Dokmeci MR, Kim HJ, Khademhosseini A. Aerogel-Based Biomaterials for Biomedical Applications: From Fabrication Methods to Disease-Targeting Applications. Adv. Sci. 2023, 2204681. https://doi.org/10.1002/advs.202204681.
7. Peirsman A, Nguyen HT, Van Waeyenberge M, Ceballos-González C, Bolívar-Monsalve J, Kawakita S, Vanlauwe F, Tirpáková Z, Van Dorpe S, Van Damme L, Mecwan M, Ermis M, Maity S, Mandal K, Herculano R, Depypere B, Budiharto L, Van Vlierberghe S, De Wever O, Blondeel P, Jucaud V, Dokmeci MR, Khademhosseini A. Vascularized adipose tissue engineering: moving towards soft tissue reconstruction. Biofabrication. 2023. doi: 10.1088/1758-5090/acd7a5.
8. Nguyen HT, Peirsman A, Tirpakova Z, Mandal K, Vanlauwe F, Maity S, Kawakita S, Khorsandi D, Herculano R, Umemura C, Yilgor C, Bell R, Hanson A, Li S, Nanda HS, Zhu Y, Najafabadi AH, Jucaud V, Barros N, Dokmeci MR, Khademhosseini A. Engineered Vasculature for Cancer Research and Regenerative Medicine. Micromachines. 2023; 14(5):978. https://doi.org/10.3390/mi14050978.
9. Mou L, Mandal K, Mecwan MM, Hernandez AL, Maity S, Sharma S, Herculano RD, Kawakita S, Jucaud V, Dokmeci MR, Khademhosseini A. Integrated biosensors for monitoring microphysiological systems. Lab on a Chip. 2022. doi: 10.1039/D2LC00262K.
10. Kawakita S, Mandal K, Mou L, Mecwan MM, Zhu Y, Li S, Sharma S, Hernandez AL, Nguyen HT, Maity S, de Barros NR, Nakayama A, Bandaru P, Ahadian S, Kim H-J, Herculano RD, Holler E, Jucaud V, Dokmeci MR, Khademhosseini A. Organ-On-A-Chip Models of the Blood–Brain Barrier: Recent Advances and Future Prospects. Small. 2022:2201401. doi: 10.1002/smll.202201401.
11. Zhu Y, Li S, Li J, Falcone N, Cui Q, Shah S, Hartel MC, Yu N, Young P, de Barros NR, Wu Z, Haghniaz R, Ermis M, Wang C, Kang H, Lee J, Karamikamkar S, Ahadian S, Jucaud V, Dokmeci MR, Kim H-J, Khademhosseini A. Lab-on-a-Contact Lens: Recent Advances and Future Opportunities in Diagnostics and Therapeutics. Advanced Materials. 2022;34(24):2108389. doi: 10.1002/adma.202108389.
12. Zhu Y, Mandal K, Hernandez AL, Kawakita S, Huang W, Bandaru P, Ahadian S, Kim H-J, Jucaud V, Dokmeci MR, Khademhosseini A. State of the art in integrated biosensors for organ-on-a-chip applications. Current Opinion in Biomedical Engineering. 2021;19:100309. doi: 10.1016/j.cobme.2021.100309.
13. Zhu Y, Haghniaz R, Hartel MC, Mou L, Tian X, Garrido PR, Wu Z, Hao T, Guan S, Ahadian S, Kim H-J, Jucaud V, Dokmeci MR, Khademhosseini A. Recent Advances in Bioinspired Hydrogels: Materials, Devices, and Biosignal Computing. ACS Biomaterials Science & Engineering. 2021. doi: 10.1021/acsbiomaterials.1c00741.
14. Nasrollahi F, Haghniaz R, Hosseini V, Davoodi E, Mahmoodi M, Karamikamkar S, Darabi MA, Zhu Y, Lee J, Diltemiz SE, Montazerian H, Sangabathuni S, Tavafoghi M, Jucaud V, Sun W, Kim H-J, Ahadian S, Khademhosseini A. Micro and Nanoscale Technologies for Diagnosis of Viral Infections. Small. 2021;17(45):2100692. doi: https://doi.org/10.1002/smll.202100692.
15. Ma X, Ahadian S, Liu S, Zhang J, Liu S, Cao T, Lin W, Wu D, de Barros NR, Zare MR, Diltemiz SE, Jucaud V, Zhu Y, Zhang S, Banton E, Gu Y, Nan K, Xu S, Dokmeci MR, Khademhosseini A. Smart Contact Lenses for Biosensing Applications. Advanced Intelligent Systems. 2021;3(5):2000263. doi: https://doi.org/10.1002/aisy.202000263.
16. Zhou X, Jiang X, Qu M, Aninwene GE, Jucaud V, Moon JJ, Gu Z, Sun W, Khademhosseini A. Engineering Antiviral Vaccines. ACS Nano. 2020;14(10):12370-89. doi: 10.1021/acsnano.0c06109.
17. El-Awar N, Jucaud V, Nguyen A. HLA Epitopes: The Targets of Monoclonal and Alloantibodies Defined. J Immunol Res. 2017;2017:3406230. Epub 2017/06/20. doi: 10.1155/2017/3406230. PubMed PMID: 28626773; PMCID: PMC5463109.
18. Ravindranath M, Jucaud V, Terasaki P. Immunobiology of Allograft Human Leukocyte Antigens in the New Microenvironment. SOJ Immunol. 2015;3(4):1-19.
19. Jucaud V, Ravindranath M, Terasaki P. Immunobiology of HLA class-Ib molecules in transplantation. SOJ Immunol. 2015;3(4):1-15.
20. Ravindranath MH, Zhu D, Pham T, Jucaud V, Hopfield J, Kawakita S, Terasaki PI. Anti-HLA-E monoclonal antibodies reacting with HLA-la and lb alleles like IVIg as potential IVIg-immunomimetics: an evolving therapeutic concept. Clin Transpl. 2013:293-305. Epub 2013/01/01. PubMed PMID: 25095521.